AEON Biopharma Inc AEON:

*Data is delayed
Last | EST
()
52 week range
-
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out22.00M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out22.00M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-2.43
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-25.502M
  • ROE (TTM)-
  • Revenue (TTM)1.13M
  • Gross Margin (TTM)100.00%
  • Net Margin (TTM)-4,738.86%
  • Debt To Equity (MRQ)-101.97%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AEON Biopharma Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
AEON Biopharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by...
Marc Forth
President, Chief Executive Officer
Chris Carr
Chief Financial Officer
Address
4040 Macarthur Boulevard, Suite 310
Newport Beach, CA
92660
United States